Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were diagnosed with ovarian cancer on or before 31 December 2021.
- People who had a BRCA gene test carried out at the Medical Genetics unit of the IRCCS AOU Bologna Policlinico S.Orsola hospital on or before 31 December 2021.
- People who received follow-up care and/or treatment at the Medical Oncology or Gynaecological Oncology departments of the IRCCS AOU Bologna hospital for at least one year, with that care occurring on or before 31 December 2021 and lasting for a minimum of six months.
Who may not be able to join:
- People whose ovarian cancer has been identified as the 'mucinous' or 'borderline' type.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniela Turchetti, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Phone: +390512143694
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Differences in BRCA1/2 status for predictive response to chemotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.